Health Trials

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

ConditionsEarly Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Cervical CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic Colorectal CarcinomaMetastatic Endometrial CarcinomaMetastatic Esophageal CarcinomaMetastatic Liver CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Skin NeoplasmMetastatic Malignant Solid NeoplasmResectable Lung Non-Small Cell CarcinomaEarly Stage Lung Non-Small Cell CarcinomaResectable Malignant Solid NeoplasmResectable Triple-Negative Breast CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Cervical Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Recurrent Cervical CarcinomaRecurrent Colorectal CarcinomaRecurrent Endometrial CarcinomaRecurrent Esophageal CarcinomaRecurrent Liver CarcinomaRecurrent Lung Non-Small Cell CarcinomaRecurrent Malignant Skin NeoplasmRecurrent Malignant Solid Neoplasm
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic

About this trial

This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.

Eligibility criteria

Qualifiers

Lung: Non-small Cell Lung Cancer (NSCLC)

Skin: Cutaneous Malignancy, excluding Uveal Melanoma

Esophageal Cancer

Cervical Cancer

Disqualifiers

Pregnant women because this study involves a greater than minimal risk procedure (biopsy)

Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety for the biopsy

Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy

NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial

Trial design

Treatments tested in this trial

  • Biospecimen Collection
  • Tissue Collection

Treatment groups

324 Participants
are divided into 1 treatment group

Locations

3
Mayo Clinic in Arizona85054, PhoenixArizona, United States
Mayo Clinic in Florida32224, JacksonvilleFlorida, United States
Mayo Clinic in Rochester55905, RochesterMinnesota, United States

Sponsors and collaborators

Mayo Clinic

Lead sponsor

Elephas Biosciences Corporation

Collaborator

Source ClinicalTrials.gov